MedAll App
Download the MedAll App
All your healthcare resources in one place
Get the latest updates from
Home

MASH Academy: Updates in Metabolic Dysfunction-Associated Steatohepatitis Management

17th Jul 2024
11:30pm - 1:00am (GMT)
17th - 18th Jul 2024
11:30pm - 1:00am (GMT)
Hosted on MedAll
Attendance certificate available
Free
ONLINE

Description

This program is funded by an independent grant from Novo Nordisk. This online education program has been designed solely for healthcare professionals in the USA. The content is not available for healthcare professionals in any other country.

Join our global experts for this accredited CME six part Academy on MASH in conjunction with the American Liver Foundation. This second session is presented by Professor Arun Sanyal.

Implement evidence-based strategies for long-term management of MASH

In this teaching lesson, participants will learn to implement evidence-based strategies for the long-term management of Metabolic Associated SteatoHepatitis (MASH). The session will underline the importance for healthcare professionals in designing patient-centered treatments and modifications that offer tailored advice for sustainable health improvements. Our expert speaker will discuss integrating the latest pharmacological treatments into patient care plans, following current guidelines with detailed attention to timing and the optimization of patient outcomes. This comprehensive approach will ensure that healthcare professionals leave with a solid framework for managing MASH effectively, balancing lifestyle interventions with pharmacotherapy for a holistic and patient-focused treatment plan.

Who is this course for

This online education program has been designed solely for healthcare professionals in the USA. The course provides continuing education for:

✅ Gastroenterologists

✅ Hepatologists

✅ Primary Care Physicians

✅ Endocrinologists

✅ Cardiologists

✅Nurse Practitioners

✅ Physician Assistants

✅ Dietitians/Nutritionists

✅Pharmacists

✅ Other Health Professionals

Faculty

Professor Arun Sanyal

Arun J. Sanyal, M.D., serves as a Professor of Medicine, Physiology, and Molecular Pathology at Virginia Commonwealth University (VCU) Medical Center in Richmond, Virginia. He holds a distinguished position in the Division of Gastroenterology and is currently the Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Dr. Sanyal is highly recognized in his field, ranking in the top 0.1% of all biomedical scientists with approximately 12,000 citations in 2022 alone. His extensive involvement includes chairing the NIH NASH Clinical Research Network, the NIMBLE consortium, and the Liver Forum for NASH and fibrosis. Dr. Sanyal's research interests span all aspects of NAFLD and NASH, as well as complications associated with end-stage liver disease. He has served on various advisory boards, including for pharmaceutical companies and the liver center at Yale University. His contributions to the medical community include leadership roles such as Secretary and President of the American Association for the Study of Liver Diseases, and he was a founding member of the Hepatology committee of the American Board of Internal Medicine. Dr. Sanyal has authored over 450 articles in prestigious journals including Cell Metabolism, Nature Medicine, New England Journal of Medicine, Lancet, Gastroenterology, Hepatology, and the Journal of Infectious Diseases. He boasts an H-index of 154 and has been continuously funded by the NIH since 1995, currently leading four active NIH grants. His achievements have been recognized with several awards, including the Distinguished Mentorship Award from the American Gastroenterological Association, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2017, and the Distinguished Achievement Award from the AASLD in 2018.

Faculty, planners, and staff disclosure information

AffinityCE/MedAll staff and the planners and reviewers of this educational activity have no relevant financial or non-financial interests to disclose.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Accreditation statements

AMA PRA Category 1 Credits™ are available for this activity.

Physicians: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Nurse Practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Other Health Professionals: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll Education. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this online activity a maximum of 1.5 AMA PRA Category 1 Credits™. Health Professionals should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries

This continuing education activity is active starting on the 17th of July 2024 and will expire on the 17th of July 2025. Estimated time to complete this activity: 1.5 hours.

For all continuing education and content inquiries, including questions to speaker(s), please contact us at ce@affinityced.com

Learning objectives

At the end of this session attendees will be able to: 1. Implement evidence-based strategies for long-term management of MASH 2. Design patient-centered lifestyle and dietary modifications, providing tailored advice for sustainable health improvements 3. Apply the latest pharmacological treatments as per current guidelines, including timing and dosage considerations for optimal patient outcomes
103 people are attending this event. Sign up today and join your colleagues at this event.
View all

Similar events and on demand videos

 
17th - 18th Jul 2024
11:30pm - 1:00am (GMT)
Hosted on MedAll
Attendance certificate available
Free
ONLINE